Bank Norwegian AS
Bank Norwegian AS: Approval of new company structure
Reference is made to previous announcements regarding MREL and the decision from the Board of Directors to apply to the Norwegian Financial Supervisory Authority (FSA) to merge Norwegian Finans Holding ASA and Bank Norwegian AS. The Norwegian FSA has on 5 January 2021 approved an application on the new company structure, leaving Bank Norwegian AS the ultimate parent company of the group after a merger. We are pleased to have received this approval, as a merger is expected to give positive synergies on administrative costs as well as reduce funding cost on future MREL eligible capital being issued from an operating company instead of a holding company.
Based on the approval, Norwegian Finans Holding ASA and Bank Norwegian AS will move forward with the formal merger process, including preparing the necessary documentation, applications and decisions by the companies’ governing bodies.
The ambition is to complete the merger process during first half of 2021, with accounting and fiscal effect from 1 January 2021, conditional on obtaining necessary approvals from relevant authorities.
CFO Klara Lise Aasen; phone +47 47635583; firstname.lastname@example.org
Head of Treasury Mats Benserud; phone +47 95891539; email@example.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Synairgen plc25.1.2021 08:06:49 CET | Press release
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
F. Hoffmann-La Roche Ltd25.1.2021 08:06:08 CET | Press release
Roche renews partnership with Sysmex to deliver haematology testing solutions
Royal Philips25.1.2021 08:06:08 CET | Press release
Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19.0%, and operating cash flow increases to EUR 1,305 million
F. Hoffmann-La Roche Ltd25.1.2021 08:02:27 CET | Press release
Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
Junshi Biosciences25.1.2021 08:01:47 CET | Press release
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
Montreal Heart Institute23.1.2021 07:02:08 CET | Press release
Colchicine reduces the risk of COVID-19-related complications
Zealand Pharma22.1.2021 22:06:25 CET | Press release
Zealand Pharma announces update to 2020 financial guidance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom